Like a portable, non-radioactive PET,
that also measures what PET cannot!
Head to head: PET vs EEG
Can you tell which is which?
Ceregram high-resolution imaging is the ideal solution for tracking direct effects of therapy for Alzheimer’s and Parkinson’s.
The first and only direct monitoring technology, proven in clinical studies, to track disease progression with all relevant endpoints: physiological, psychological, and more.
Learn about our rigorous scientific approach
Collaborate with us Today
Vision
A new standard of care where dementia patients and their doctors can quickly see when therapies are working (and when they aren’t) through routine, complete evaluations at the point of care. This way, effects of intervention are easy to track over time, disease management is intelligently adjusted based on progress, and patients experience the best possible outcomes: slowing, stopping, and in best cases, reversal of disease.
Mission
To empower physicians with the best possible clinical decision making abilities at their own clinic. Our unique technology enables precise tracking of neurological diseases over time, so it is quick and easy to see how your patients respond to different therapies, across all relevant disease endpoints, including amyloid and tau accumulations, neurodegeneration, and cognitive symptoms.
Brain Imaging by Patented Evoked Potential Tomography
Diseases like Alzheimer’s, Parkison’s, Lewy Body Disease, and virtually all other brain diseases (including Schizophrenia and Traumatic Brain Injuries) cause sensory deficits, by damaging key areas of the brain responsible for perception.
Localizing and quantifying these deficits is an effective way to map the specific neuron columns aversely affected by disease, which is everything we need to differentiate patient conditions and construct high-resolution, high-fidelity brain images, that tracks how patients respond to therapy, even before visible symptoms.
Researchers and clinicians use Ceregram to monitor people with dementia and other neurological disorders, because they recognize the need to monitor across all hallmarks of disease, such as: brain volume changes (e.g. CT and MRI), physiological changes (e.g. amyloid and tau accumulation in the brain), and patient performance in psychological testing (e.g. MMSE, CERAD, and TASIT).
Relevant Press & Publications
Vistim Labs Launches at American Academy of Neurology 2025
HITLAB Partners with Vistim Labs for Brain Disease Monitoring Validation Study
Vistim Labs unveils new biomarkers at the Alzheimer’s Association International Conference
Vistim Labs wins 1st at Inventions Health Competition
Vistim Labs publishes new findings in Alzheimer’s Research and Therapy Journal
Vistim Labs wins 1st at Startup San Diego Competition
